# Lecture 14: Parasitology - Protozoa ## Unit 2.8: Microbiology --- ## Learning Objectives By the end of this lecture, students will be able to: 1. Describe the general characteristics and classification of protozoa 2. Explain intestinal protozoa (Giardia, Entamoeba, Cryptosporidium) 3. Describe blood and tissue protozoa (Plasmodium, Trypanosoma, Leishmania) 4. Explain opportunistic protozoa (Toxoplasma) 5. Describe sexually transmitted protozoa (Trichomonas) 6. Explain diagnostic approaches and treatment of protozoal infections --- ## Lecture Outline ### I. Protozoa Overview Protozoa are unicellular eukaryotic organisms that represent some of the most important human parasites globally, causing diseases ranging from self-limited diarrhea to life-threatening systemic infections. Unlike bacteria, protozoa are true eukaryotes with membrane-bound nuclei, mitochondria, and complex intracellular organelles. They are considerably larger than bacteria, typically measuring 10-100 micrometers, and can often be visualized on routine microscopy of clinical specimens. Most protozoa reproduce asexually through binary fission, though some species exhibit more complex reproductive cycles including schizogony (multiple fission producing many daughter cells) and alternating sexual and asexual generations. The classification of protozoa has traditionally been based on their mechanisms of locomotion, providing a practical framework for understanding these diverse organisms. Sarcodina (amoebae) move using pseudopods, temporary cytoplasmic extensions that allow the organism to engulf food particles and propel itself; Entamoeba histolytica is the primary pathogenic member of this group. Flagellates possess one or more whip-like flagella for motility and include medically important genera such as Giardia, Trichomonas, Trypanosoma, and Leishmania. Ciliates are covered with numerous short hair-like cilia that beat in coordinated waves; Balantidium coli is the only ciliate pathogen of humans. The Apicomplexa (sporozoans) lack obvious locomotor organelles in their infective stages but possess a specialized apical complex used for host cell invasion; this group includes Plasmodium (malaria), Toxoplasma, Cryptosporidium, and Cyclospora. Protozoa reach humans through various transmission routes that reflect their environmental niches and life cycles. Fecal-oral transmission through contaminated water or food accounts for infections with Giardia, Entamoeba, Cryptosporidium, and Cyclospora. Vector-borne transmission by arthropods is essential for Plasmodium (Anopheles mosquitoes), Trypanosoma (tsetse flies, reduviid bugs), Leishmania (sandflies), and Babesia (Ixodes ticks). Sexual transmission occurs with Trichomonas vaginalis. Congenital transmission is important for Toxoplasma gondii, which can cause devastating fetal infections when primary maternal infection occurs during pregnancy. Several protozoa, including Cryptosporidium and Toxoplasma, cause opportunistic infections in immunocompromised hosts. Most pathogenic protozoa exist in multiple morphologic stages during their life cycles, with distinct forms adapted for survival in the environment, transmission, and proliferation within hosts. The trophozoite is the active, feeding, and replicating stage found within the host; it is typically fragile and does not survive well outside the body. The cyst is a dormant, environmentally resistant stage with a protective wall that allows survival during transmission; cysts are the infective form for fecal-orally transmitted protozoa. Oocysts are specialized cyst-like structures produced by apicomplexan parasites containing sporozoites. Merozoites are the invasive forms released from infected host cells during schizogony. Gametocytes are the sexual stages that, in vector-borne parasites like Plasmodium, are taken up by the arthropod vector to continue the sexual reproductive cycle. Panel A: Comparative illustration showing the four major groups of protozoa classified by locomotion: an amoeba with extending pseudopods, a flagellate with multiple flagella, a ciliate covered with cilia, and an apicomplexan showing the apical complex structure. Panel B: Diagram illustrating the common life cycle stages of protozoa including trophozoite (active feeding stage), cyst (dormant resistant stage), and the transition between these forms in the host and environment. Panel C: World map showing the global distribution of major protozoal diseases with color-coded regions indicating endemic areas for malaria, leishmaniasis, trypanosomiasis, and amebiasis. Panel D: Flowchart depicting the various transmission routes for protozoa including fecal-oral (water/food), vector-borne (mosquito, fly, tick), sexual contact, and congenital pathways. --- ### II. Giardia lamblia (intestinalis) Giardia lamblia (also known as Giardia intestinalis or Giardia duodenalis) is the most common intestinal protozoan parasite in the United States and a leading cause of waterborne diarrheal disease worldwide. The trophozoite has a distinctive morphology often described as "face-like" or resembling a tennis racket, with bilateral symmetry, two nuclei that appear as eyes, a central axostyle, and four pairs of flagella (eight total) that provide motility. A unique ventral adhesive disk allows the organism to attach firmly to the intestinal epithelium of the duodenum and jejunum. The cyst form is oval, contains four nuclei when mature, and is remarkably resistant to environmental conditions including chlorination at standard water treatment concentrations. The epidemiology of giardiasis reflects the organism's environmental stability and low infectious dose. Transmission occurs through the fecal-oral route, primarily via contaminated water sources including lakes, streams, and inadequately treated municipal water supplies. Beavers are an important animal reservoir (hence the colloquial name "beaver fever"), though dogs and other mammals can also harbor the parasite. Outbreaks commonly occur among campers and hikers who drink untreated surface water, children in daycare centers, institutionalized individuals, and travelers to endemic areas. The infectious dose is remarkably low, with as few as 10-25 cysts sufficient to cause infection, facilitating person-to-person transmission especially in settings with close contact. Clinical giardiasis typically manifests after an incubation period of one to two weeks. The hallmark presentation includes watery, foul-smelling diarrhea that is often described as greasy or oily due to fat malabsorption (steatorrhea). Patients commonly experience bloating, flatulence, abdominal cramps, and nausea. The diarrhea characteristically does not contain blood or mucus, distinguishing it from invasive causes of dysentery. The disease may be acute and self-limited, or it can become chronic, persisting for weeks to months with intermittent symptoms and leading to significant weight loss and malnutrition. Malabsorption of fats and fat-soluble vitamins (A, D, E, K) can occur, and in children, chronic infection may impair growth and development. Asymptomatic carriage is common and contributes to ongoing transmission. Diagnosis of giardiasis has evolved from traditional microscopic examination to more sensitive antigen-based methods. Stool examination for ova and parasites (O&P) can reveal cysts or, less commonly, trophozoites, but sensitivity is limited and may require examination of multiple specimens collected on different days. Stool antigen detection using enzyme immunoassay (EIA) or direct fluorescent antibody (DFA) testing is more sensitive than microscopy and has become the preferred diagnostic method. The string test (Entero-Test), in which a string is swallowed and retrieved to sample duodenal contents, is rarely used today but can increase diagnostic yield. Treatment consists of metronidazole as the traditional first-line agent, though tinidazole offers the advantage of single-dose therapy with fewer gastrointestinal side effects. Nitazoxanide is an effective alternative, particularly useful in children and pregnant women (though data in pregnancy are limited). Prevention focuses on water treatment through filtration (cysts are too large to pass through standard filters) and avoiding consumption of untreated surface water. Panel A: Detailed illustration of the Giardia lamblia trophozoite showing the characteristic "face-like" appearance with two nuclei, median bodies, four pairs of flagella, and the prominent ventral adhesive disk used for attachment to intestinal epithelium. Panel B: Microscopic images comparing the trophozoite form (pear-shaped, motile) with the oval cyst form showing the four nuclei characteristic of mature cysts, as seen on iodine-stained stool preparation. Panel C: Diagram showing Giardia attachment to the intestinal brush border epithelium of the duodenum, illustrating how the adhesive disk creates a seal against the microvillus surface and interferes with nutrient absorption. Panel D: Flowchart depicting the diagnostic algorithm for giardiasis, progressing from clinical suspicion through stool antigen testing (preferred) and stool O&P examination, with treatment options including metronidazole, tinidazole, and nitazoxanide. --- ### III. Entamoeba histolytica Entamoeba histolytica is the causative agent of amebiasis, a disease that ranges from asymptomatic colonization to life-threatening invasive disease including amoebic dysentery and liver abscess. This organism must be distinguished from the morphologically identical but non-pathogenic Entamoeba dispar, which is far more common but does not cause invasive disease. The trophozoite of E. histolytica moves by extending pseudopods and has a single nucleus with a characteristic central karyosome and fine peripheral chromatin. A pathognomonic finding is the presence of ingested erythrocytes within the cytoplasm of trophozoites, indicating tissue invasion and helping to distinguish it from non-pathogenic species. The cyst form has four nuclei when mature and contains characteristic cigar-shaped chromatoid bodies composed of crystallized ribosomes. Amebiasis is a major global health problem, with approximately 50 million cases and 100,000 deaths annually, predominantly in developing countries with poor sanitation. Transmission occurs through the fecal-oral route via ingestion of cysts in contaminated water or food; trophozoites are fragile and do not survive gastric acid. Risk factors include residence in or travel to endemic areas (Mexico, Central and South America, South Asia, Africa), institutionalization, and men who have sex with men. After ingestion, cysts excyst in the small intestine and trophozoites colonize the large intestine, where they may remain as harmless commensals or invade the intestinal mucosa. The factors determining invasive versus non-invasive infection are incompletely understood but involve both parasite virulence factors and host immune status. The clinical spectrum of amebiasis includes asymptomatic infection, intestinal disease, and extraintestinal disease. Approximately 90 percent of infections are asymptomatic, though these individuals shed cysts and serve as reservoirs for transmission. Amoebic colitis (intestinal amebiasis) presents with gradual onset of bloody diarrhea, abdominal pain, and tenesmus; the diarrhea contains blood and mucus due to mucosal invasion and ulceration. Colonoscopy reveals characteristic flask-shaped ulcers with undermined edges and normal intervening mucosa. Fulminant or necrotizing colitis can occur, particularly in patients receiving corticosteroids, and carries high mortality. Amoebic liver abscess is the most common extraintestinal manifestation, typically presenting with fever, right upper quadrant pain, hepatomegaly, and elevated alkaline phosphatase. The abscess most commonly involves the right lobe of the liver, and aspiration reveals the classic "anchovy paste" or "chocolate sauce" material representing necrotic hepatocytes and debris. Rupture into the peritoneum, pleura, or pericardium can occur and requires urgent intervention. Diagnosis of amebiasis requires distinguishing E. histolytica from morphologically identical non-pathogenic species. Traditional stool O&P examination cannot differentiate these species and has limited sensitivity for invasive disease. Stool antigen tests specific for E. histolytica (detecting the Gal/GalNAc lectin) or PCR provide definitive identification. Serology is positive in approximately 95 percent of patients with amoebic liver abscess but cannot distinguish current from past infection in endemic areas. Imaging with CT or ultrasound demonstrates liver abscess. Treatment of invasive amebiasis (colitis or liver abscess) requires metronidazole or tinidazole to eradicate tissue trophozoites, followed by a luminal agent (paromomycin or iodoquinol) to eliminate intestinal cysts and prevent relapse. Asymptomatic carriers should also receive luminal treatment to prevent transmission and potential future invasive disease. Most liver abscesses respond to medical therapy alone without drainage, though aspiration may be needed for large abscesses, those failing to respond to therapy, or when rupture is imminent. Panel A: Microscopic image of Entamoeba histolytica trophozoite demonstrating pseudopod extension and the pathognomonic finding of multiple ingested erythrocytes within the cytoplasm, stained with trichrome stain. Panel B: Comparison illustration showing the mature four-nucleated cyst of E. histolytica with characteristic cigar-shaped chromatoid bodies alongside the diagnostic features used to distinguish it from non-pathogenic Entamoeba species. Panel C: Colonoscopic image showing the characteristic flask-shaped amoebic ulcers with undermined edges and areas of normal intervening mucosa in a patient with amoebic colitis, alongside a histologic section showing trophozoites at the ulcer base. Panel D: CT scan of the abdomen demonstrating a large amoebic liver abscess in the right lobe with characteristic peripheral enhancement and central low attenuation, alongside an illustration of the "anchovy paste" appearance of aspirated material. --- ### IV. Cryptosporidium Cryptosporidium species are apicomplexan parasites that have gained recognition as important causes of diarrheal disease worldwide, particularly in immunocompromised individuals. The two species most commonly infecting humans are Cryptosporidium parvum (zoonotic, infecting both humans and animals) and Cryptosporidium hominis (anthroponotic, primarily human-to-human transmission). The infectious form is the oocyst, which is remarkably small (4-5 micrometers, among the smallest protozoan parasites) and contains four sporozoites. A critical characteristic is the organism's resistance to standard chlorine disinfection at concentrations used in water treatment, contributing to its role in waterborne outbreaks. The epidemiology of cryptosporidiosis reflects multiple transmission routes and environmental resilience. Waterborne transmission accounts for large outbreaks, including the 1993 Milwaukee outbreak affecting over 400,000 people through contaminated municipal water supply. Recreational water exposure (swimming pools, water parks) is increasingly recognized due to the organism's chlorine resistance. Direct contact with infected animals (particularly young livestock) and person-to-person transmission in daycare settings and households also occur. The infectious dose is extremely low, with as few as 10-30 oocysts sufficient to cause infection. Immunocompromised individuals, particularly those with AIDS and CD4 counts below 100 cells per microliter, are at risk for severe, chronic, and potentially fatal infection. Clinical cryptosporidiosis varies dramatically based on host immune status. In immunocompetent individuals, the infection causes acute, watery, non-bloody diarrhea lasting one to two weeks and is typically self-limited, though symptoms can be quite severe with profuse watery stools, cramping, nausea, and low-grade fever. In patients with AIDS and severe immunosuppression (CD4 less than 100 cells per microliter), the infection can become chronic and unrelenting, with cholera-like volumes of watery diarrhea (up to 10-15 liters daily in severe cases), profound weight loss, and wasting. Biliary involvement (AIDS cholangiopathy) can occur with cholangitis, papillary stenosis, and sclerosing cholangitis. The organism can also involve the respiratory tract, causing cough and dyspnea. Before the advent of effective antiretroviral therapy, cryptosporidiosis was a major cause of AIDS-related morbidity and mortality. Diagnosis of cryptosporidiosis relies on identification of oocysts in stool specimens. The modified acid-fast stain reveals small, round, pink to red oocysts against a blue-green background, though the small size makes identification challenging and requires careful microscopy. Direct fluorescent antibody (DFA) testing and enzyme immunoassay (EIA) for stool antigen detection offer improved sensitivity and are widely used. Polymerase chain reaction (PCR) is the most sensitive method and allows species identification. Treatment options are limited; in immunocompetent patients, the infection is self-limited and management is supportive with fluid and electrolyte replacement. Nitazoxanide is FDA-approved for immunocompetent patients but has limited efficacy in AIDS patients. For HIV-infected patients, the cornerstone of management is immune reconstitution through effective antiretroviral therapy (ART), which allows the immune system to control and eventually clear the infection. Prevention emphasizes water treatment through filtration (oocysts are removed by filters with pore sizes of 1 micrometer or smaller), boiling water (which kills oocysts), and avoiding recreational water exposure during outbreaks. Panel A: Microscopic image of Cryptosporidium oocysts on modified acid-fast stain showing the characteristic small (4-5 micrometer), round, pink to red structures against the blue-green counterstained background of fecal debris. Panel B: Diagram illustrating the life cycle of Cryptosporidium within the intestinal epithelium, showing oocyst ingestion, excystation, sporozoite invasion of enterocytes, intracellular development stages (trophozoite, meront, merozoite), and oocyst formation. Panel C: Illustration depicting the clinical spectrum of cryptosporidiosis comparing self-limited diarrhea in immunocompetent hosts with chronic, severe, cholera-like illness in AIDS patients with low CD4 counts. Panel D: Cholangiogram showing AIDS cholangiopathy with characteristic beaded appearance of intrahepatic bile ducts, papillary stenosis, and sclerosing cholangitis pattern associated with biliary cryptosporidiosis. --- ### V. Plasmodium (Malaria) Malaria is the most important parasitic disease globally, causing approximately 200 million cases and 600,000 deaths annually, with the vast majority of mortality occurring in children under five years of age in sub-Saharan Africa. Five Plasmodium species cause human malaria: P. falciparum is responsible for the majority of severe disease and deaths, characterized by high parasitemia and ability to infect erythrocytes of all ages; P. vivax and P. ovale form dormant liver stages (hypnozoites) that can cause relapsing infection months to years after initial exposure; P. malariae causes a milder illness but can persist for decades; P. knowlesi is a zoonotic species from Southeast Asian macaques that can cause severe disease in humans. Transmission occurs through the bite of infected female Anopheles mosquitoes, with the geographic distribution determined by the presence of competent vector species. The life cycle of Plasmodium is complex and involves both human and mosquito hosts. Infection begins when sporozoites in mosquito saliva are injected during a blood meal; these sporozoites rapidly travel to the liver and invade hepatocytes. During the liver stage (exoerythrocytic schizogony), parasites multiply within hepatocytes over 7-10 days, producing thousands of merozoites that are released into the bloodstream. P. vivax and P. ovale can form hypnozoites, dormant stages that remain in hepatocytes and can reactivate to cause relapse. Released merozoites invade erythrocytes and undergo intraerythrocytic schizogony, cycling through ring, trophozoite, and schizont stages before lysing the red cell to release more merozoites; this cycle repeats every 48 hours (P. falciparum, P. vivax, P. ovale) or 72 hours (P. malariae). Some parasites develop into male and female gametocytes, which are taken up by mosquitoes to complete the sexual cycle (sporogony) and produce sporozoites in the mosquito salivary glands. Clinical malaria presents after an incubation period of 7-30 days, depending on the species and prior immunity. The classic presentation includes paroxysms of fever with rigors and chills, followed by profuse sweating as the fever breaks, corresponding to the synchronized release of merozoites from ruptured red cells. Headache, myalgias, and malaise are common, and physical examination typically reveals splenomegaly and varying degrees of anemia from hemolysis. P. falciparum malaria can progress to severe or complicated malaria, defined by specific clinical or laboratory criteria including: cerebral malaria (impaired consciousness, seizures), severe anemia (hemoglobin less than 7 g/dL), respiratory distress (including ARDS), metabolic acidosis, hypoglycemia, acute kidney injury, hypotension, and hyperparasitemia (greater than 5 percent parasitized erythrocytes). P. falciparum-infected erythrocytes express surface proteins that cause adherence to vascular endothelium (cytoadherence), leading to microvascular sequestration and obstruction that underlies much of the organ dysfunction in severe malaria. Diagnosis of malaria requires demonstration of parasites in blood, traditionally through microscopic examination of Giemsa-stained thick and thin blood smears. The thick smear concentrates parasites for screening sensitivity, while the thin smear allows species identification and parasitemia quantification. Rapid diagnostic tests (RDTs) detecting parasite antigens provide results within minutes and are valuable in resource-limited settings, though they cannot quantify parasitemia. PCR is the most sensitive method and is used for low-level parasitemia, species confirmation, and drug resistance studies. Treatment depends on the species, severity, and local resistance patterns. Uncomplicated falciparum malaria is treated with artemisinin-based combination therapy (ACT) such as artemether-lumefantrine or artesunate-amodiaquine. Severe falciparum malaria requires intravenous artesunate, which has replaced quinine as the treatment of choice based on superior efficacy in clinical trials. P. vivax and P. ovale require additional treatment with primaquine to eliminate hypnozoites and prevent relapse; primaquine causes hemolysis in G6PD deficiency, necessitating testing before use. Chemoprophylaxis for travelers to endemic areas includes atovaquone-proguanil, doxycycline, or mefloquine, with selection based on destination-specific resistance patterns and patient factors. Panel A: Illustration of the complete Plasmodium life cycle showing the mosquito bite injecting sporozoites, liver stage schizogony (with hypnozoite formation for P. vivax/ovale), merozoite release into blood, intraerythrocytic cycle through ring, trophozoite, and schizont stages, gametocyte formation, and sexual reproduction in the mosquito. Panel B: Microscopic images of Giemsa-stained thin blood smears showing the characteristic morphology of different Plasmodium stages including ring forms (signet ring appearance), mature trophozoites, schizonts with merozoites, and banana-shaped P. falciparum gametocytes. Panel C: World map showing the global distribution of malaria with endemic zones color-coded by dominant species and drug resistance patterns, highlighting high-transmission areas in sub-Saharan Africa and Southeast Asia. Panel D: Clinical illustration showing manifestations of severe falciparum malaria including cerebral malaria with coma and seizures, severe anemia, respiratory distress, and the pathophysiology of cytoadherence causing microvascular obstruction. --- ### VI. Trypanosoma African trypanosomiasis, commonly known as sleeping sickness, is caused by subspecies of Trypanosoma brucei transmitted by tsetse flies (Glossina species) in sub-Saharan Africa. Two subspecies cause distinct disease patterns: T. brucei gambiense is responsible for over 95 percent of cases, occurring in West and Central Africa with humans as the primary reservoir, and causes a chronic illness evolving over months to years. T. brucei rhodesiense is found in East Africa, has animal reservoirs (cattle, wild game), and causes an acute, rapidly progressive illness over weeks to months. Both subspecies are extracellular parasites that multiply in blood, lymph, and eventually the central nervous system. A remarkable feature is antigenic variation, in which the parasite continuously changes its surface glycoprotein coat (variant surface glycoproteins, VSGs), allowing it to evade host antibody responses and establish chronic infection. The clinical course of African trypanosomiasis progresses through two stages. The hemolymphatic stage begins with a chancre (painful nodule) at the tsetse bite site, followed by intermittent fever, headache, lymphadenopathy, and hepatosplenomegaly. Posterior cervical lymphadenopathy, known as Winterbottom sign, is a classic finding particularly associated with T. b. gambiense infection. The meningoencephalitic (CNS) stage develops when parasites cross the blood-brain barrier, causing progressive neurological deterioration including personality changes, cognitive impairment, psychiatric symptoms, movement disorders, and characteristic sleep disturbances (reversal of sleep-wake cycle, daytime somnolence). Without treatment, disease progression to coma and death is inevitable. Diagnosis requires demonstration of trypanosomes in blood, lymph node aspirate, or cerebrospinal fluid; serologic screening (CATT test for T. b. gambiense) helps identify infected individuals in endemic populations. CSF examination is mandatory to determine disease stage, as treatment differs significantly. American trypanosomiasis (Chagas disease) is caused by Trypanosoma cruzi, transmitted by triatomine ("kissing") bugs throughout Latin America from southern United States to Argentina. Unlike African trypanosomes, T. cruzi is an intracellular parasite that replicates within host cells as amastigotes (non-flagellated forms). Transmission occurs when infected bug feces are rubbed into the bite wound, conjunctiva, or other mucous membranes; transmission can also occur through blood transfusion, organ transplantation, congenital transmission, and ingestion of contaminated food. The acute phase presents with fever, malaise, and characteristic findings at the inoculation site: the chagoma (skin nodule) or Romana sign (unilateral periorbital edema when infection occurs through the conjunctiva). Most acute infections are mild or asymptomatic. Following acute infection, T. cruzi establishes lifelong chronic infection. An indeterminate phase lasting years to decades is characterized by positive serology without clinical manifestations. Approximately 20-30 percent of infected individuals eventually develop chronic Chagas disease, primarily affecting the heart and gastrointestinal tract. Chronic Chagas cardiomyopathy includes conduction abnormalities (right bundle branch block, left anterior fascicular block), arrhythmias (often ventricular), dilated cardiomyopathy, heart failure, and apical aneurysm formation. Gastrointestinal manifestations result from destruction of the myenteric plexus, causing megaesophagus (dysphagia, regurgitation) and megacolon (severe constipation, volvulus). Diagnosis of acute Chagas disease uses blood smear or PCR to detect parasites; chronic disease relies on serology (two different tests required for confirmation). Treatment with benznidazole or nifurtimox is most effective in acute disease and early chronic infection; treatment benefit in established chronic cardiomyopathy is uncertain. Vector control, blood bank screening, and housing improvements are essential prevention strategies. Panel A: Illustration showing the tsetse fly vector and African trypanosome morphology with the characteristic undulating membrane, single flagellum, and kinetoplast, alongside the clinical progression from chancre through hemolymphatic stage (Winterbottom sign showing posterior cervical lymphadenopathy) to meningoencephalitic stage with sleep disturbances. Panel B: Map of Africa showing the distinct geographic distributions of T. b. gambiense (West and Central Africa) and T. b. rhodesiense (East Africa) with tsetse fly habitat zones. Panel C: Illustration of Chagas disease transmission showing the triatomine "kissing" bug, the inoculation of T. cruzi from contaminated feces, and characteristic acute phase findings including Romana sign (unilateral periorbital edema) and chagoma. Panel D: Clinical manifestations of chronic Chagas disease showing dilated cardiomyopathy with apical aneurysm on echocardiogram, electrocardiogram with right bundle branch block, and barium swallow demonstrating megaesophagus with characteristic bird-beak appearance. --- ### VII. Leishmania Leishmaniasis encompasses a spectrum of diseases caused by various Leishmania species, transmitted by phlebotomine sandflies in tropical and subtropical regions worldwide. The parasite exists in two morphologic forms: promastigotes (elongated, flagellated forms) in the sandfly vector and amastigotes (small, oval, non-flagellated forms) within macrophages of the mammalian host. After inoculation by sandfly bite, promastigotes are phagocytosed by macrophages and transform into amastigotes that survive and replicate within the phagolysosome, eventually rupturing the cell to infect additional macrophages. The species of Leishmania and the host immune response together determine the clinical manifestation, which ranges from self-healing cutaneous ulcers to fatal visceral disease. Cutaneous leishmaniasis is the most common form, caused by different species in different geographic regions. In the Old World (Mediterranean, Middle East, Africa, Asia), L. major and L. tropica are the primary causes, while in the New World (Central and South America), L. mexicana complex and L. braziliensis complex predominate. The classic lesion begins as a papule at the sandfly bite site that enlarges over weeks to form a painless ulcer with raised, indurated borders and a necrotic base, often described as a "volcano crater" appearance or "oriental sore." Lesions typically occur on exposed areas (face, extremities) and may be single or multiple. Most cases of Old World cutaneous leishmaniasis are self-limiting, healing over months to years with scarring. Mucocutaneous leishmaniasis (espundia), caused primarily by L. braziliensis in South America, is a particularly destructive variant in which parasites metastasize from the primary skin lesion to involve the nasal and oral mucosa, causing progressive destruction of the nose, palate, and pharynx with severe disfigurement. Visceral leishmaniasis (kala-azar, meaning "black fever" in Hindi) is caused by L. donovani in South Asia and East Africa, and L. infantum (L. chagasi) in the Mediterranean, Middle East, and Latin America. This systemic infection affects the reticuloendothelial organs and presents with prolonged fever, progressive hepatosplenomegaly (the spleen may become massively enlarged), pancytopenia, weight loss, and hypergammaglobulinemia. The darkening of skin on the face and extremities gives the disease its Hindi name. Without treatment, visceral leishmaniasis is almost uniformly fatal due to secondary infections, bleeding, or cachexia. Post-kala-azar dermal leishmaniasis (PKDL) is a dermatologic sequela occurring after treatment, particularly common in South Asia, presenting as hypopigmented macules and papulonodular lesions containing parasites that serve as a reservoir for ongoing transmission. Diagnosis of leishmaniasis depends on the clinical form. Cutaneous leishmaniasis is diagnosed by demonstrating amastigotes in tissue samples obtained by slit-skin smear, punch biopsy, or aspirate from the lesion border; organisms appear as small, oval structures with a nucleus and rod-shaped kinetoplast ("Leishman-Donovan bodies"). Culture and PCR increase sensitivity and allow species identification. Visceral leishmaniasis diagnosis traditionally required splenic or bone marrow aspiration to demonstrate amastigotes within macrophages; serologic tests (rK39 rapid test, direct agglutination test) are now used for initial diagnosis in endemic areas, though sensitivity is reduced in HIV co-infection. Treatment varies by species, geographic region, and clinical form. Liposomal amphotericin B is first-line for visceral leishmaniasis in most regions due to excellent efficacy and safety. Miltefosine, an oral agent, is effective for both visceral and cutaneous disease but is teratogenic. Pentavalent antimonials (sodium stibogluconate, meglumine antimoniate) remain important in some regions despite toxicity concerns. Cutaneous leishmaniasis may be managed with local therapy (intralesional antimonials, cryotherapy, heat therapy) for small, uncomplicated lesions, or systemic therapy for extensive or mucocutaneous disease. Prevention focuses on personal protective measures (bed nets, insect repellent, protective clothing) and, in some regions, reservoir control. Panel A: Illustration showing the Leishmania life cycle including the sandfly vector biting and inoculating promastigotes, macrophage phagocytosis, intracellular transformation to amastigotes, and replication within the phagolysosome, with eventual cell lysis and infection spread. Panel B: Clinical photographs demonstrating cutaneous leishmaniasis with the characteristic painless ulcer showing raised, indurated borders and central necrosis, and mucocutaneous leishmaniasis showing destructive lesions of the nasal septum and palate. Panel C: Microscopic image of a Giemsa-stained bone marrow or splenic aspirate showing macrophages filled with numerous small amastigotes (Leishman-Donovan bodies), each with visible nucleus and kinetoplast. Panel D: Clinical features of visceral leishmaniasis (kala-azar) including massive hepatosplenomegaly demonstrated on physical examination and CT imaging, with the characteristic cachectic appearance and skin hyperpigmentation. --- ### VIII. Toxoplasma gondii Toxoplasma gondii is an obligate intracellular apicomplexan parasite with a worldwide distribution, infecting approximately one-third of the global human population. Cats are the definitive host in which sexual reproduction occurs, with oocysts shed in cat feces for one to two weeks following primary infection. Intermediate hosts include virtually all warm-blooded animals, including humans, in which tissue cysts containing bradyzoites form in brain, muscle, and other tissues. Three primary transmission routes exist: ingestion of oocysts from cat feces or contaminated soil/water, ingestion of tissue cysts in undercooked meat (particularly pork, lamb, and venison), and congenital transmission from mother to fetus during primary maternal infection. The parasite exists as three morphologic forms: tachyzoites (rapidly dividing forms during acute infection), bradyzoites (slowly dividing forms within tissue cysts during latent infection), and sporozoites (within oocysts). Clinical toxoplasmosis varies dramatically based on the host's immune status and whether infection is acquired or reactivated. In immunocompetent individuals, primary infection is asymptomatic in approximately 80-90 percent of cases. Symptomatic infection typically presents as a mononucleosis-like syndrome with cervical lymphadenopathy, fever, malaise, and fatigue; unlike EBV mononucleosis, pharyngitis and significant atypical lymphocytosis are usually absent. Chorioretinitis (ocular toxoplasmosis) can occur with primary infection or reactivation and presents with blurred vision, eye pain, and characteristic retinal lesions described as "headlight in fog" (white area of active retinitis adjacent to old pigmented scar). The disease is typically self-limited in immunocompetent hosts, though tissue cysts persist for life. Toxoplasmosis in immunocompromised patients, particularly those with AIDS and CD4 counts below 100 cells per microliter, results from reactivation of latent tissue cysts rather than primary infection. Toxoplasmic encephalitis is the most common clinical presentation, manifesting with headache, fever, altered mental status, seizures, and focal neurologic deficits. CT or MRI characteristically shows multiple ring-enhancing lesions with predilection for the basal ganglia and corticomedullary junction. The main differential diagnosis is primary CNS lymphoma, which typically appears as a single or fewer lesions. Empiric treatment for toxoplasmosis is often initiated without biopsy if serology is positive (indicating prior exposure), with brain biopsy reserved for patients who fail to respond to therapy. Other manifestations in AIDS patients include chorioretinitis and pneumonitis. Congenital toxoplasmosis occurs when a seronegative woman acquires primary infection during pregnancy, with the parasite crossing the placenta to infect the fetus. The risk of transmission increases with gestational age (10-15 percent in first trimester to 60-70 percent in third trimester), while severity of fetal disease is inversely related (most severe with first trimester infection). The classic triad of congenital toxoplasmosis includes chorioretinitis, hydrocephalus, and diffuse intracranial calcifications, though manifestations range from subclinical infection to severe disease with hepatosplenomegaly, jaundice, thrombocytopenia, and neurologic sequelae including seizures and developmental delay. Intracranial calcifications in congenital toxoplasmosis are characteristically diffuse or scattered throughout the brain parenchyma, in contrast to the periventricular calcifications seen in congenital CMV infection. Diagnosis employs serology with IgG and IgM antibodies; IgG avidity testing helps distinguish recent from past infection (low avidity suggests recent infection). PCR of amniotic fluid can diagnose fetal infection. Treatment of toxoplasmic encephalitis consists of pyrimethamine plus sulfadiazine plus leucovorin (folinic acid to prevent pyrimethamine-induced bone marrow suppression). Primary prophylaxis with trimethoprim-sulfamethoxazole is indicated for HIV patients with CD4 counts below 100 cells per microliter who are Toxoplasma IgG positive. Pregnant women should be advised to avoid cat litter, garden soil, and undercooked meat. Panel A: Life cycle illustration of Toxoplasma gondii showing the definitive host (cat) with sexual reproduction and oocyst shedding, intermediate hosts (humans, livestock) with tissue cyst formation, and transmission routes including oocyst ingestion, undercooked meat, and congenital transmission. Panel B: Brain MRI showing multiple ring-enhancing lesions in the basal ganglia characteristic of toxoplasmic encephalitis in an AIDS patient, with surrounding edema and mass effect. Panel C: Funduscopic photograph demonstrating toxoplasmic chorioretinitis with the classic "headlight in fog" appearance showing active white retinitis adjacent to an old pigmented chorioretinal scar. Panel D: CT scan of an infant with congenital toxoplasmosis showing characteristic diffuse intracranial calcifications and hydrocephalus, alongside an illustration of the classic triad including chorioretinitis. --- ### IX. Other Protozoa Trichomonas vaginalis is the causative agent of trichomoniasis, the most common non-viral sexually transmitted infection worldwide with an estimated 150-170 million cases annually. The organism is a pear-shaped flagellate with four anterior flagella and a single posterior flagellum that forms the outer edge of an undulating membrane, providing a characteristic "jerky" motility on wet mount examination. Uniquely among pathogenic protozoa, T. vaginalis exists only as a trophozoite and does not form cysts, making it susceptible to desiccation and necessitating direct contact transmission. In women, trichomoniasis presents with a frothy, malodorous, yellow-green vaginal discharge, vulvar irritation, pruritus, and dysuria; the classic "strawberry cervix" (punctate hemorrhages on the cervix) is pathognomonic but seen in only 2-5 percent of cases. Many women are asymptomatic but serve as reservoirs for transmission. In men, infection is usually asymptomatic or causes mild urethritis. Diagnosis can be made by wet mount demonstrating motile trichomonads, though sensitivity is only 50-60 percent; nucleic acid amplification testing (NAAT) is now the preferred diagnostic method. Treatment consists of metronidazole or tinidazole as single-dose therapy, with concurrent treatment of sexual partners essential to prevent reinfection. Balantidium coli is the only ciliate pathogen of humans and the largest protozoan capable of infecting humans. The organism is covered with cilia that provide motility and has a characteristic kidney-shaped macronucleus visible on microscopy. Pigs are the primary reservoir, and transmission occurs through fecal-oral ingestion of cysts in contaminated water or food. The infection is most common in tropical regions with close human-pig contact. Clinical disease resembles amebiasis, ranging from asymptomatic carriage to dysentery with bloody, mucoid diarrhea. Colonic ulcers similar to those of amebiasis can occur. Diagnosis is by identification of large trophozoites or cysts in stool specimens. Treatment consists of tetracycline or metronidazole. Babesia species are intraerythrocytic apicomplexan parasites transmitted by Ixodes ticks, the same vector that transmits Lyme disease and anaplasmosis in endemic areas. In the United States, Babesia microti is the primary species, endemic to the Northeast and upper Midwest, while Babesia divergens causes more severe disease in Europe. Risk factors for severe disease include asplenia, advanced age, and immunocompromise. Clinical babesiosis presents with fever, fatigue, hemolytic anemia, and thrombocytopenia. The hallmark finding on blood smear is intraerythrocytic ring forms that can be confused with malaria, but the presence of "Maltese cross" or tetrad forms (four parasites arranged in a cross pattern within a single red cell) is pathognomonic for Babesia. Unlike malaria, there is no pigment (hemozoin) in infected cells. Diagnosis is by blood smear examination, PCR, or serology. Treatment for mild to moderate disease is atovaquone plus azithromycin; severe disease requires intravenous clindamycin plus quinine, with exchange transfusion considered for high parasitemia or severe hemolysis. Additional intestinal protozoa causing diarrheal disease include Cyclospora cayetanensis and Cystoisospora (formerly Isospora) belli. Cyclospora is transmitted through contaminated fresh produce (raspberries, basil, lettuce) and causes watery diarrhea with prolonged symptoms (weeks if untreated), fatigue, and weight loss. The oocyst is larger than Cryptosporidium (8-10 micrometers) and shows variable acid-fast staining and characteristic autofluorescence under UV light. Treatment is trimethoprim-sulfamethoxazole. Cystoisospora belli causes a similar diarrheal illness, primarily in immunocompromised hosts (AIDS-defining illness). Oocysts are large, oval, and contain one or two sporocysts. Treatment is also TMP-SMX. Proper food handling and washing of produce are important prevention measures. Panel A: Microscopic image of Trichomonas vaginalis on wet mount showing the characteristic pear-shaped trophozoite with anterior flagella and undulating membrane, demonstrating the jerky motility pattern, alongside a clinical photograph of "strawberry cervix" with punctate hemorrhages. Panel B: Microscopic image of Balantidium coli trophozoite showing the large size, ciliated surface, and distinctive kidney-shaped macronucleus compared to intestinal epithelial cells for scale. Panel C: Blood smear showing Babesia microti within erythrocytes, including ring forms and the pathognomonic "Maltese cross" or tetrad formation with four parasites arranged in a cross pattern within a single red blood cell. Panel D: Comparison of modified acid-fast stained oocysts showing the size difference between Cryptosporidium (4-5 micrometers) and Cyclospora (8-10 micrometers), with Cyclospora demonstrating variable staining and characteristic autofluorescence under UV microscopy. --- ### X. Diagnosis and Treatment Summary The diagnosis of protozoal infections employs various methodologies depending on the organism, site of infection, and available resources. Microscopic examination of stool for ova and parasites (O&P) remains fundamental for intestinal protozoa, requiring fresh specimens and often multiple samples to achieve adequate sensitivity; concentration techniques improve detection of cysts and oocysts. Modified acid-fast staining identifies Cryptosporidium, Cyclospora, and Cystoisospora oocysts. Blood smear examination using Giemsa or Wright stain is essential for diagnosis of malaria, trypanosomiasis, and babesiosis, with both thick smears (for screening) and thin smears (for species identification) recommended. Stool antigen testing has improved diagnosis of Giardia, Cryptosporidium, and E. histolytica with greater sensitivity than microscopy. Serologic testing is valuable for tissue protozoa including Toxoplasma (IgG/IgM, avidity testing), Leishmania (rK39, DAT), and Chagas disease (requiring two positive tests by different methods for confirmation). Molecular methods, particularly polymerase chain reaction (PCR), have revolutionized protozoal diagnosis with superior sensitivity and specificity compared to traditional methods. PCR can detect very low-level parasitemia in malaria, differentiate E. histolytica from non-pathogenic Entamoeba species, identify Cryptosporidium species, and provide rapid diagnosis of CNS infections. Nucleic acid amplification testing (NAAT) has become the preferred diagnostic method for Trichomonas vaginalis. Rapid diagnostic tests (RDTs) provide point-of-care diagnosis for malaria and visceral leishmaniasis, enabling treatment initiation without laboratory infrastructure. Imaging plays a supportive role: CT and MRI for toxoplasmic encephalitis and neurocysticercosis (discussed in the helminth lecture), ultrasound and CT for amoebic liver abscess, and cholangiography for AIDS cholangiopathy due to Cryptosporidium. Treatment of protozoal infections relies on a relatively limited armamentarium of antiparasitic drugs. Metronidazole (and related nitroimidazoles like tinidazole) is the cornerstone treatment for Giardia, E. histolytica, and Trichomonas, acting through reduction of its nitro group within anaerobic or microaerophilic organisms to produce cytotoxic intermediates. Paromomycin, a non-absorbed aminoglycoside, serves as a luminal agent to eradicate intestinal cysts after metronidazole treatment for invasive amebiasis. Nitazoxanide is effective against Giardia and Cryptosporidium in immunocompetent patients. Antimalarial therapy has evolved to address resistance, with artemisinin-based combination therapy (ACT) as the current standard for uncomplicated falciparum malaria and intravenous artesunate for severe disease. Primaquine is essential for P. vivax and P. ovale to eliminate hypnozoites, with G6PD testing required. Pentamidine, suramin, melarsoprol, and eflornithine are used for African trypanosomiasis, with drug selection based on species and disease stage. Benznidazole and nifurtimox treat Chagas disease. Pyrimethamine plus sulfadiazine is the regimen for toxoplasmosis. Liposomal amphotericin B, miltefosine, and antimonials treat leishmaniasis. Atovaquone-azithromycin treats babesiosis. Prevention of protozoal infections combines personal protective measures, environmental interventions, and public health strategies. Water treatment through filtration and boiling (chlorination is ineffective against Cryptosporidium and Giardia cysts) prevents waterborne infections. Safe food handling prevents Cyclospora and Toxoplasma transmission. Vector control measures including insecticide-treated bed nets, indoor residual spraying, and personal repellents reduce transmission of malaria, leishmaniasis, and trypanosomiasis. Chemoprophylaxis prevents malaria in travelers to endemic areas. Safe sexual practices prevent trichomoniasis. Screening blood donations prevents transfusion-transmitted Chagas disease and babesiosis. Prenatal screening and education for pregnant women prevent congenital toxoplasmosis. No vaccines are currently available for human protozoal infections, though malaria vaccine development is advancing with the RTS,S vaccine receiving WHO recommendation for use in endemic areas. Panel A: Flowchart illustrating the diagnostic approach to protozoal infections organized by specimen type (stool, blood, tissue) and method (microscopy, antigen detection, serology, molecular), with specific tests indicated for each major pathogen. Panel B: Summary diagram showing the mechanisms of action of major antiprotozoal drugs on their respective targets: metronidazole (DNA damage), antimalarials (various stages of Plasmodium life cycle), pyrimethamine-sulfadiazine (folate synthesis), and amphotericin (cell membrane). Panel C: World map showing global disease burden and endemic regions for major protozoal diseases with overlapping zones indicated, including malaria (tropics/subtropics), leishmaniasis (Mediterranean, South Asia, Latin America), Chagas (Latin America), and African trypanosomiasis (sub-Saharan Africa). Panel D: Public health prevention pyramid showing interventions at individual level (chemoprophylaxis, bed nets, safe food/water), community level (vector control, sanitation), and global level (surveillance, elimination programs, vaccine development). --- ## Summary - Protozoa are unicellular eukaryotes classified by motility: sarcodina (pseudopods), flagellates, ciliates, and apicomplexa; transmission occurs through fecal-oral, vector-borne, sexual, and congenital routes - Giardia lamblia causes watery, foul-smelling diarrhea with bloating and malabsorption; diagnosed by stool antigen testing; treated with metronidazole or tinidazole - Entamoeba histolytica causes amoebic dysentery (bloody diarrhea, flask-shaped ulcers) and liver abscess ("anchovy paste" pus); treat with metronidazole followed by luminal agent (paromomycin) - Cryptosporidium causes self-limited diarrhea in immunocompetent hosts but severe, chronic disease in AIDS patients (CD4 less than 100); acid-fast oocysts; treatment is supportive (nitazoxanide) with ART being key for AIDS patients - Malaria (Plasmodium) is mosquito-borne; P. falciparum causes severe disease (cerebral malaria, severe anemia); diagnosis by blood smear; treat with ACT (artemisinin combination); add primaquine for P. vivax/P. ovale after G6PD testing - African trypanosomiasis (sleeping sickness) transmitted by tsetse fly; Chagas disease (T. cruzi) transmitted by reduviid bug causes chronic cardiomyopathy and megacolon; treat Chagas with benznidazole - Leishmaniasis (sandfly-transmitted): cutaneous (ulcers), mucocutaneous (destructive), visceral (kala-azar with hepatosplenomegaly, pancytopenia); treat visceral with liposomal amphotericin B - Toxoplasma gondii: cats are definitive host; causes mononucleosis-like illness in immunocompetent, ring-enhancing brain lesions in AIDS, congenital triad of chorioretinitis/hydrocephalus/calcifications; treat with pyrimethamine-sulfadiazine - Trichomonas vaginalis: STI causing frothy discharge and "strawberry cervix"; diagnose by NAAT; treat with metronidazole - Babesia: tick-borne (Ixodes); "Maltese cross" on blood smear; severe in asplenic patients; treat with atovaquone-azithromycin --- ## Key Terms | Term | Definition | |------|------------| | Trophozoite | The motile, feeding, and replicating stage of protozoa found within the host | | Cyst | The dormant, environmentally resistant stage of protozoa with a protective wall | | Oocyst | The resistant sporozoan stage containing sporozoites, produced by apicomplexan parasites | | Schizogony | Asexual reproduction by multiple fission, producing many daughter cells (merozoites) | | Hypnozoite | The dormant liver stage of P. vivax and P. ovale capable of causing relapsing infection | | Vector | An arthropod that transmits a pathogen from one host to another (mosquito, sandfly, tsetse, tick) | | Amastigote | The intracellular, non-flagellated stage of Leishmania and Trypanosoma cruzi within macrophages | | Ring form | The early intraerythrocytic stage of Plasmodium species visible on blood smear | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*